Lattice radiation versus conventional radiation to relieve symptoms from large solid tumors.
Official title: Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
Run by University Health Network, Toronto · NCT07444775 · Data updated 2026-11-12
This trial tests whether lattice (spatially fractionated) radiotherapy gives better pain relief than conventional radiotherapy for people with solid tumors at least 5 cm who need palliative radiation.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 148 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | November 18, 2025 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT07444775 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with pathologically confirmed solid tumors 5 cm or larger who need palliative radiation, are unsuitable for surgery or definitive RT, and can undergo CT simulation and treatment at the trial center.
✕Probably not a fit
Patients with tumors smaller than 5 cm, those eligible for curative SBRT or surgery, or tumors not suitable for a lattice dose pattern are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized phase III trial compares spatially fractionated lattice radiotherapy (SFRT or LATTICE) to conventional palliative radiation in patients with solid tumors at least 5 cm. Participants are randomized to receive either lattice treatment, which delivers very high doses to discrete spots within the tumor while lowering dose at the tumor edges, or standard radiation planning, with treatment guided by CT simulation. The primary outcome is pain improvement at 30 ±7 days measured by the International Consensus Pain Response using the Brief Pain Inventory and changes in opioid or co-analgesic use. Eligible patients must have pathologically or radiographically confirmed solid tumors ≥5 cm that are unsuitable for surgery or definitive RT and be able to undergo planning and treatment at the trial center.
Why it matters
Potential benefit: If successful, lattice RT could provide faster and greater pain relief for patients with large tumors while limiting dose to nearby healthy tissue.
How similar studies have gone: Early-phase and single-center reports have shown rapid and substantial pain and tumor responses with SFRT in bulky tumors of the lung, head and neck, and cervix, but randomized phase III data are not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of solid tumor by at least one criterion below: a. Pathologically or cytologically proven solid tumor greater than 5 cm (largest dimension) from a primary site or site of metastasis and unsuitable for surgical resection or definitive RT. b. HCC diagnosed by standard imaging criteria permitted: arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis * Eastern Cooperative Oncology Group (ECOG) Status: 0-4 within 14 days of randomization * In the investigator's opinion, patient requires palliative radiation therapy to a lesion \>5 cm measured in one of the following ways: * Imaging performed within 90 days prior to randomization per Response Evaluation Criteria in Solid Tumors (RECIST) * CT simulation performed for radiation planning * Able to understand and provide written consent * Willing and have the ability to complete the baseline and post-treatment questionnaires (short form brief-pain inventory) and to maintain a pain diary * Patient is not pregnant, planning on becoming pregnant or planning on fathering a child in the next 90 days * Patient must be accessible for treatment and follow-up. Investigators must ensure the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up * Minimum worst pain score of 2/10 in the past 24 hours on the Brief Pain Inventory. Exclusion Criteria: * Prior radiotherapy that would result in substantial overlap of the irradiated volume thus precluding per protocol treatment * Requirement for urgent surgical intervention prior to radiation treatment * Confirmed pregnancy * Hematologic primary malignancy * Medical condition precluding the delivery of per protocol treatment (e.g. connective tissue disorder) * Tumors overlying critical CNS, heart or spinal cord compression
Where it's running
-
Princess Margaret Cancer Center
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Jelena Lukovic, MD FRCPC MPH MRMD
- Email: Jelena.lukovic@uhn.ca
- Phone: 416 946 4483
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.